Literature DB >> 12802290

Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.

Malini Udtha1, Sang-Joon Lee, Rita Alam, Kevin Coombes, Vicki Huff.   

Abstract

The Wilms' tumor suppressor gene, WT1, functions as a transcriptional regulator that represses or activates the expression of a variety of putative target genes. However, it is not clear which genes are the biological targets of WT1, nor which cellular pathway(s) is critically altered in tumors as a result of WT1 mutation. To investigate in vivo the role of WT1 as a transcription factor in Wilms' tumors, we used cDNA microarrays to compare the expression of putative WT1 target genes in a set of 15 primary Wilmstumors carrying WT1-inactivating mutations versus a set of 16 tumors with no WT1 mutations. We hypothesized that the expression of direct downstream targets of WT1 that are relevant to tumor development would differ between these two genetically distinct sets of tumors. Using the Atlas Human Cancer 1.2 cDNA arrays to quantitate gene expression in the 31 tumors, we found that the expression of one WT1 putative target gene, c-MYC, statistically significantly differed between the two sets of tumors and was upregulated in WT1-mutant tumors. This increase of relative gene expression for c-MYC was confirmed using real-time reverse transcription-polymerase chain reaction. The differential expression of another putative target gene, EGR1, approached significance and was also upregulated in WT1-mutant tumors. These data, in addition to the coexpression of c-MYC and WT1 in embryonic renal mesenchyme, strongly suggest that c-MYC is a biologically relevant target of WT1 in Wilmstumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802290     DOI: 10.1038/sj.onc.1206597

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Differential gene expression in stromal cells of human giant cell tumor of bone.

Authors:  M Wuelling; G Delling; E Kaiser
Journal:  Virchows Arch       Date:  2004-09-23       Impact factor: 4.064

2.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

3.  HtrA2, taming the oncogenic activities of WT1.

Authors:  Jörg Hartkamp; Stefan G E Roberts
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

4.  Inhibition of PACAP activity by a receptor antagonist results in changes in cell cycle and apoptotic proteins in chick neuroblasts.

Authors:  Nola M Erhardt; Lee R Haines; Terry W Pearson; Nancy M Sherwood
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome.

Authors:  Fei Gao; Sourindra Maiti; Guizhi Sun; Nelson G Ordonez; Malini Udtha; Jian Min Deng; Richard R Behringer; Vicki Huff
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

6.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi.

Authors:  Jörg Hartkamp; Brian Carpenter; Stefan G E Roberts
Journal:  Mol Cell       Date:  2010-01-29       Impact factor: 17.970

8.  A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.

Authors:  Marianne K-H Kim; Jacqueline M Mason; Chi-Ming Li; Windy Berkofsky-Fessler; Le Jiang; Divaker Choubey; Paul E Grundy; Benjamin Tycko; Jonathan D Licht
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

Review 9.  Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1).

Authors:  Eneda Toska; Stefan G E Roberts
Journal:  Biochem J       Date:  2014-07-01       Impact factor: 3.857

10.  WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line.

Authors:  Sarah J Goodfellow; Michelle R Rebello; Eneda Toska; Leo A H Zeef; Sean G Rudd; Kathryn F Medler; Stefan G E Roberts
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.